Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Study Questions 'Off-Label' Use of Antipsychotics

They're being increasingly prescribed for psychiatric disorders such as depression, dementia

By Amanda Gardner
HealthDay Reporter


Related Encyclopedia
 border=
Alzheimer's Disease
Dementia
Depression (Major Depressive Disorder)
Dysthymia
More...

Related Healthscout Videos
 border=
Howard: The Helping Hand for Stroke Survivors
Fixing Torn Hearts
Medicine's Next Big Thing? Growing Hearts
How can a supportive family help?
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Bipolar Disorder Animation
Depression
Erectile Dysfunction
More...

Related Drug Information
 border=
Actonel
Ambien
Avandia
Coumadin
More...

Related News Articles
 border=
Statin Therapy Helps Diabetic Patients
Vitamin C May Play Role in Stroke Prevention
Health Tip: Postpartum Depression
Priming Heart Before an Attack Could Limit Damage
More...

FRIDAY, Jan. 19 (HealthDay News) -- Newer antipsychotic medications are being used widely for a variety of psychiatric disorders for which they were not initially approved.

This "off label" use comes without strong evidence that the drugs are effective for these conditions and with a risk for serious side effects, said a report issued this week by the Agency for Healthcare Research and Quality (AHRQ).

Text Continues Below



The medications were approved to treat conditions such as schizophrenia and bipolar disorder, but are now being prescribed to millions of Americans for depression, dementia, and other psychiatric disorders without strong evidence that such off-label uses are effective, the report stated.

"The issue of off-label indications is a problem across medications, but I think it's particularly of concern with drugs that affect mental-health issues," said Dr. David Atkins, chief medical officer at AHRQ's Center for Outcomes and Evidence.

The revelation, contained in an AHRQ report titled Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics, was not startling to clinicians.

"The surprise is that people have not been more adamant about this earlier," said Dr. Julio Licinio, chairman of psychiatry and behavioral sciences at the University of Miami Miller School of Medicine.

The report comes on the heels of another study that found that antipsychotic drugs, commonly prescribed to treat psychosis, agitation and aggression in Alzheimer's patients, are essentially no more effective than a sugar pill.

Atypical antipsychotics such as aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal) and ziprasidone (Geodon) are designed to cause fewer neurological complications than older antipsychotics. They are approved to treat schizophrenia and bipolar disorder but are increasingly used to treat dementia, geriatric aggression, depression, obsessive-compulsive disorder, post-traumatic stress disorder and personality disorders.

Page:  1 | 2 | 3 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 1/19/2007

Related Links
 border=
From Healthscout's partner site on alzheimer's disease, OurAlzheimers.com
I need to know about Alzheimer's symptoms.
What are the stages of Alzheimer's Disease?
Learn about Alzheimer's medications.





New Features

New ADHD Site!

SOURCES: David Atkins, M.D., chief medical officer, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, Md.; Julio Licinio, M.D., chairman, department of psychiatry and behavioral sciences, University of Miami Miller School of Medicine; Cheryl Corcoran, M.D., assistant professor of psychiatry, Columbia University, and researcher in schizophrenia, New York State Psychiatric Institute, New York City; Jan. 17, 2007, Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics, Agency for Healthcare Research and Quality


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map